

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1579-628

HALE ET ALI

C# M#

Serial No. 09/998,923


TC/A.U. 1642

Filed: December 3, 2000

Examiner: UNGAR

Date: June 2, 2004

Title: ZINC ALPHA-2-GLYCOPROTEIN AS INDICATOR OF CANCER

1642
\$
JF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ **Correspondence Address Indication Form Attached.****Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$ 86.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$290.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s) (\$110.00/1 month; \$420.00/2 months; \$950.00/3 months) \$ 1480.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$770.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

Subtotal \$ 1480.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 00

☒ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00

TOTAL FEE ENCLOSED \$ 740.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HALE et al

Atty. Ref.: 1579-628 Confirmation No. 4251

Appl. No. 09/998,923

TC/A.U. 1642

Filed: December 3, 2001

Examiner: Ungar

For: ZINC ALPHA-2-GLYCOPROTEIN AS INDICATOR OF CANCER

* * * * *

June 2, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE

This is in response to the Examiner's requirement for restriction, set forth in the Office Action dated January 1, 2004, the period for response having been extended up to June 2, 2004, by submission of the required petition and fee herewith. Applicants elect the subject matter of Group 1 (claims 1-7) for prosecution in this application. As regards the Examiner's requirements of election of species, Applicants elect plasma as the sample and immunoassay as the assay type.

The election is made with traverse.

The Examiner is urged to reconsider the requirement for restriction, at least between the subject matter of Group 1 and the subject matter of Groups 2-8 (claims 8-


-- HALE et al
Appl. NO. 09/998,923
June 2, 2004

13). The subject matter of Group 1 and the subject matter of Groups 2-8 are classed and subclassed identically. Thus, it is believed that no undue burden would be placed on the Examiner if all of Groups 1-8 were to be considered in the same application.

An early and favorable Action on the merits is awaited.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 
Mary J. Wilson
Reg. No. 32,955

MJW:tat
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100